SCHEMBL15345112

SCHEMBL15345112

Cc1ccnc(-c2ccc3ccc(=O)[nH]c3c2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.49
CA9 Q16790 2/20 0.49
MAPK1 P28482 3/20 0.46
CCR1 P32246 1/20 0.46
CCR5 P51681 1/20 0.46
CCR8 P51685 1/20 0.46
CYP2A6 P11509 1/20 0.45
PDE3B Q13370 7/20 0.43
PDE3A Q14432 7/20 0.43
MGLL Q99685 1/20 0.40
METAP2 P50579 1/20 0.39
CA1 P00915 1/20 0.39
CA3 P07451 1/20 0.39
CA4 P22748 1/20 0.39
CA6 P23280 1/20 0.39
CA5A P35218 1/20 0.39
CA7 P43166 1/20 0.39
CA13 Q8N1Q1 1/20 0.39
CA14 Q9ULX7 1/20 0.39
CA5B Q9Y2D0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15345000 0.90 CA12 (0.59) CA12CA9MAPK1CCR1CCR5
SCHEMBL15341929 0.82 MAPK1 (0.41) CA12CA9MAPK1PDE3BPDE3A
SCHEMBL7238611 0.82 CCR1 (0.50) MAPK1CCR1CCR5CCR8CYP2A6
SCHEMBL27084041 0.80 CCR1 (0.50) MAPK1CCR1CCR5CCR8CYP2A6
SCHEMBL9231553 0.79 CA12 (0.49) CA12CA9CYP2A6PDE3BPDE3A
SCHEMBL15344936 0.78 CCR1 (0.52) CCR1CCR5CCR8CYP2A6PDE3B
SCHEMBL15344980 0.75 MAPT (0.52) CCR1CCR5CCR8CYP2A6PDE3B
SCHEMBL436560 0.75 CA12 (0.74) CA12CA9MAPK1CYP2A6PDE3B
SCHEMBL15345113 0.73 CCR1 (0.46) CA12CA9CCR1CCR5CCR8
SCHEMBL31695263 0.73 CCR1 (0.76) CCR1CCR5CCR8CYP2A6METAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3070081-B1 BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION GILEAD SCIENCES INC (US) 2018-02-28 EP disclosed
US-20160015690-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2016-01-21 US disclosed
US-8987250-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2015-03-24 US disclosed
US-20130281433-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160015690-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 CA12 3855/4885CA9 3361/4885MAPK1 3248/4885
US-20130281433-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 CA12 3855/4885CA9 3361/4885MAPK1 3248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.